Oxford Biomedica says Sanofi pulling out of haemophilia project
Sanofi
€91.75
13:05 24/12/24
-0.03%
-€0.03
Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.
CAC 40
7,282.69
17:00 24/12/24
0.14%
10.37
DJ EURO STOXX 50
4,857.86
23:59 24/12/24
0.10%
4.93
FTSE 250
20,571.51
13:00 24/12/24
n/a
n/a
FTSE 350
4,491.87
12:54 24/12/24
n/a
n/a
FTSE All-Share
4,449.61
13:14 24/12/24
n/a
n/a
Oxford Biomedica
425.00p
12:40 24/12/24
0.00%
0.00p
Pharmaceuticals & Biotechnology
20,055.90
12:54 24/12/24
0.25%
50.73
Sanofi had given notice to "terminate the collaboration and license agreement for process development and manufacturing of lentiviral vectors to treat haemophilia", Oxford said on Friday.
"The group expects that the impact on revenue will be negligible over the coming 24 month period."